News & Updates

Show Multimedia Only

Roflumilast cream effective in Chinese patients with plaque psoriasis

18 Apr 2026 by

Once-daily application of roflumilast cream 0.3% is associated with a significantly higher rate of treatment success on the Investigator's Global Assessment (IGA) scale in Chinese patients with plaque psoriasis compared with a vehicle cream, according to the phase III DERMIS-1 and -2 studies presented at AAD 2026.

Roflumilast cream effective in Chinese patients with plaque psoriasis

18 Apr 2026

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026 by

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.

IL-23 inhibitors work best at preventing PsA development in psoriasis

17 Apr 2026

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Patients with cutaneous malignant melanoma (CMM) whose tumour is located in the head and neck (HN) are at greater risk of all-cause and cancer-specific mortality than those with tumours found in the trunk, reveals a study.

Head and neck tumours linked to increased mortality in CMM patients

17 Apr 2026

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026 by

Patients with psoriasis who are treated with methotrexate (MTX) show a reduced incidence of metabolic syndrome and better cardiometabolic profiles, according to a study presented at AAD 2026.

Methotrexate may lower CV risk in psoriasis patients

17 Apr 2026

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026 by

Data from two phase III ICONIC-ADVANCE studies presented at AAD 2026 reinforce the potential of the investigational first-in-class targeted oral peptide icotrokinra for the treatment of plaque psoriasis (PsO).

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

06 Apr 2026

Novel tyrosine kinase 2 inhibitor looks good for AD

03 Apr 2026

In the treatment of patients with atopic dermatitis, the investigational tyrosine kinase 2 inhibitor ICP-332 demonstrates a favourable safety profile with promising efficacy, according to a phase II study.

Novel tyrosine kinase 2 inhibitor looks good for AD

03 Apr 2026

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

In the treatment of patients with juvenile localized scleroderma, mycophenolate mofetil compares favourably with methotrexate in terms of reducing clinical activity and flare rate, according to a retrospective study.

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

02 Apr 2026

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Solid organ transplant (SOT) recipients with a history of cancer are at increased risk of post-transplant cancer, especially the same type of cancer, according to a study.

Malignant disease may re-emerge following SOT among cancer survivors

21 Mar 2026

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

In patients with prurigo nodularis, treatment with dupilumab provides consistent, meaningful improvements in pruritus while having a favourable safety profile, according to a meta-analysis.

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia

17 Mar 2026

The efficacy of unorthodox dosing regimens of tofacitinib and baricitinib is comparable among paediatric patients with moderate-to-severe alopecia areata over 24 weeks and has a manageable safety profile, reports a recent study.

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia

17 Mar 2026

News & Updates

Showing Dermatology articles

Showing

Specialty:

Roflumilast cream effective in Chinese patients with plaque psoriasis

Roflumilast cream effective in Chinese patients with plaque psoriasis

IL-23 inhibitors work best at preventing PsA development in psoriasis

IL-23 inhibitors work best at preventing PsA development in psoriasis

Head and neck tumours linked to increased mortality in CMM patients

Head and neck tumours linked to increased mortality in CMM patients

Methotrexate may lower CV risk in psoriasis patients

Methotrexate may lower CV risk in psoriasis patients

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

ICONIC-ADVANCE 1-year data herald a shift in plaque psoriasis treatment

Novel tyrosine kinase 2 inhibitor looks good for AD

Novel tyrosine kinase 2 inhibitor looks good for AD

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

Mycophenolate mofetil as good as methotrexate for juvenile localized scleroderma

Malignant disease may re-emerge following SOT among cancer survivors

Malignant disease may re-emerge following SOT among cancer survivors

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia

Unorthodox-dosed tofacitinib, baricitinib both efficacious in paediatric alopecia